Gastric HER2 testing study (GaTHER) : an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia

Stephen B. Fox, Marian Priyanthi Kumarasinghe, Jane E. Armes, Michael Bilous, Margaret C. Cummings, Gelareh Farshid, Nicole Fitzpatrick, Glenn D. Francis, Philip I. McCloud, Wendy Raymond, Adrienne Morey

    Research output: Contribution to journalArticlepeer-review

    40 Citations (Scopus)

    Abstract

    Trastuzumab provides a survival benefit in patients with human epidermal growth factor receptor 2 (HER2)-amplified/overexpressed advanced gastric and gastroesophageal junction cancers (GC/GJCs). However, the optimal method for testing is unclear. The aim of this study was to assess interlaboratory agreement on HER2 scoring in GC/GJC to aid the development of a robust testing algorithm for diagnostic practice in Australia. Nine laboratories assessed the HER2 status of 100 GC/GJC tissue samples by immunohistochemistry (IHC) and in situ hybridization (ISH) [chromogenic (CISH) or silver (SISH)] using both HER2 copy number and HER2:chr17 (chromosome 17) ratio. Results were compared with reference fluorescence ISH (FISH). Interlaboratory agreement on IHC3+ scoring was good (k=0.76), and there was good/very good agreement between IHC (positivity defined as IHC3+) and ISH when HER2 copy number was used (k=0.72 to 0.87). Agreement on CISH/SISH scoring was good/very good when HER2 copy number was used (k=0.68 to 0.86), and agreement between CISH/SISH and FISH using HER2 copy number was very good (k=0.88 to 0.91). Agreement was reduced when HER2:chr17 ratio was used. The good agreement for HER2 copy number determined by bright-field ISH suggests that this is the optimal method for testing in GC/GJC cases. An IHC3+ score was strongly predictive of a positive ISH result, although agreement for all IHC scores was only moderate, suggesting that IHC triage before ISH testing would be the most cost-effective strategy. However, because of the unique features of GC/GJC samples and the difficulty of ensuring consistent HER2 staining in the community setting, it is recommended that HER2 status in advanced GC/GJC be determined by both IHC and ISH in the same laboratory.
    Original languageEnglish
    Pages (from-to)577-582
    Number of pages6
    JournalAmerican Journal of Surgical Pathology
    Volume36
    Issue number4
    DOIs
    Publication statusPublished - 2012

    Fingerprint

    Dive into the research topics of 'Gastric HER2 testing study (GaTHER) : an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia'. Together they form a unique fingerprint.

    Cite this